Background: Diffuse large B cell non-Hodgkin lymphoma (DLBCL) is the greatest common category of adult lymphoma. Recurrence and treatment resistance happened in one‑third of cases, triggering them to the progressive stage of DL BCL after treatment. Detection of novel predictive and prognostic biomarkers leads to improvement of its treatment and prognosis.
Aim of the study; was to assess the prognostic roles of protein expression of MYD88 and TBLR1 in tissues of diffuse large B cell non-Hodgkin lymphoma patients.
Material and methods: in the current study we included tissues from 100 cases of DLBCL. For immunohistochemistry, tissues were stained with MYD88 and TBLR1. We followed patients for about 3 years then we correlated their expression with clinic-pathological and prognostic parameters.
Results: higher MYD88 and TBLR1 expressions were associated with presence of B symptoms, fever, night sweat, advanced stage, bone marrow involvement and bulky nodal size, presence of extra-nodal extension, unfavorable RFS and unfavorable OS rates (p |
